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ABSTRAK 
Latar Belakang: Di kalangan 28 juta penduduk Malaysia pada tahun 2010, sebanyak 
0.002% pesakit von Willebrand dilaporkan dengan 63% daripadanya berbangsa Melayu. 
Disebabkan kepelbagaian genetik pada gene vWF dan faktor-faktor lain, paras vWF di 
dalam darah dan presentasi penyakit berbeza antara individu. Objektif kajian ini adalah 
untuk mendapatkan data profil vWF di kalangan Melayu yang berkumpulan darah ABO 
yang berbeza dan untuk melihat hubungkait demografi data dan status merokok, dengan 
paras profil vWF.  
Kaedah: Seramai 140 penderma darah Melayu yang mempunyai kumpulan darah ABO 
yang berbeza, terlibat dalam kajian keratin rentas yang dijalankan di Pusat Darah Negara, 
Kuala Lumpur. Paras FVIII diukur dengan kaedah ‘coagulometric clot detection’, vWF 
antigen dan RiCof, dengan kaedah ‘latex particles agglutination’  dan CBA dengan 
kaedah ‘ELISA’.  
Keputusan: Majoriti penderma (59.3%) berumur 30-49 tahun, lelaki (81.43%), bukan 
perokok (74.3%) dan, mempunyai berat badan berlebihan atau obesiti (40.7%). We found 
the vWF profiles were higher in B blood group, followed by A and O. Didapati paras 
profil vWF tertinggi adalah pada kumpulan darah B diikuti oleh A dan O. Paras (IU/dL) 
Faktor VIII, antigen vWF, RiCof dan CBA di kalangan kumpulan darah A ialah 138.77 
+ 37.74, 143.30 + 45.20, 100.97 + 24.47, 95.80 + 32.55, kumpulan darah B ialah 144.43 
+ 31.69, 151.37 + 40.79, 107.93+ 25.95 dan 103.78 + 31.74, manakala kumpulan O ialah 
115.10 + 29.65, 104.96 + 40.11, 83.26 + 21.63 dan 87.86 + 24.31. Prevalens vWF antigen 
dan CBA yang rendah (<50 IU/dL) adalah jarang pada Melayu iaitu 1.4% dan 0.7%. 
Kesemua mereka berkumpulan darah O dan A. Tiada subjek yang mempunyai vWF 
antigen <30 IU/dL. Seorang subjek mempunyai RiCof <30 IU/dL tetapi parameter ujian 
xvii 
 
lainnya adalah normal. Dalam kes ini, perlu diulangi ujian RiCof dan ujian lanjut 
mungkin juga perlu bagi memastikan beliau tiada penyakit von Willebrand Jenis 2. 
Nisbah purata RiCof: antigen di kalangan kumpulan A, B dan O adalah 0.70 + 0.56, 0.71 
+ 0.51 dan 0.79 + 0.64, manakala nisbah CBA: antigen adalah 0.67 + 0.66, 0.68 + 0.58 
dan 0.84 + 0.66. Didapati juga paras CBA mempunyai hubungkait yang signifikan dengan 
kumpulan umur. Kajian juga mendapati paras vWF antigen di kalangan Melayu sedikit 
tinggi tetapi nisbah vWf aktiviti: antigen rendah berbanding populasi kulit putih, India, 
Cina dan Thailand.  
Kesimpulan dan cadangan: Seperti kajian sebelumnya, subjek berkumpulan O 
mempunyai paras profil vWF yang rendah berbanding bukan O. Adalah dicadangkan 
untuk mengambil nisbah aktiviti vWF: antigen <0.6 sebagai aras untuk meningkatkan 
pengesanan vWD varian di kalangan Melayu. Bagi kajian yang akan datang, dicadangkan 
untuk membuat ujian molekular di kalangan pesakit von Willebrand berbangsa Melayu 
bagi mengenalpasti kewujudan varian pada gene vWF yang mungkin menyebabkan paras 
dan aktiviti vWF protein yang berbeza di kalangan bangsa tersebut berbanding dengan 
populasi lain. Dicadangkan juga untuk membuat kajian yang melibatkan populasi yang 
lebih besar dengan penyertaan pelbagai kaum di Malaysia dan subjek berkumpulan darah 
AB kerana saiz sampel yang kecil menjadikan limitasi pada kajian kali ini. 
Kata Kunci: Profile Faktor von Willebrand, Kumpulan darah ABO, Melayu 
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ABSTRACT 
 
Background: In the year 2010, 0.002% von Willebrand disease patients were reported 
among 28 million of Malaysia population, with 63% of them from the Malay ethnicity.  
Due to multiple genetic makeup on vWF gene and other factors, the vWF level in the 
bloodstream and disease presentation vary among different individuals.  The objective of 
this research is to obtain the data of vWF profiles of the different ABO blood type among 
Malays and to observe the association of demographic characteristic and smoking habit 
with the profiles. 
Methodology:  One hundred and forthy (140) of the different ABO blood group Malay 
donors were involved in the cross sectional study administered in the NBCKL.  FVIII, 
vWF antigen and RiCof, and CBA levels were measured by coagulometric clot detection, 
latex particles agglutination and ELISA methods respectively. 
Results: Majority of the donor (59.3%) were aged between 30-49 years, male (81.43%), 
non-smoker (74.3%) and, overweight and obese (71.4%).  We found that the vWF profiles 
were higher in B blood group, followed by A and O. The levels (IU/dL) of FVIII, vWF 
antigen, RiCof and CBA in A blood group were 138.77 + 37.74, 143.30 + 45.20, 100.97 
+ 24.47, 95.80 + 32.55 respectively, in B blood group were 144.43 + 31.69, 151.37 + 
40.79, 107.93 + 25.95 and 103.78 + 31.74 respectively and, in O blood group were 115.10 
+ 29.65, 104.96 + 40.11, 83.26 + 21.63 and 87.86 + 24.31 respectively. The prevalence 
of low (<50 IU/dl) vWF antigen and CBA were rare among the Malays which were 1.4% 
(n=2) and 0.7% (n=1) respectively.  All of them were in the O and A blood groups.  None 
of the subject had vWF antigen <30 IU/dL.  One subject had RiCof <30 IU/dL but the 
other test parameters were normal.  In this case, RiCof test should be repeated and further 
investigation may require to exclude vWD Type 2. The average ratio of RiCof: antigen 
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among A, B and O groups were 0.70 + 0.56, 0.71 + 0.51 and 0.79 + 0.64 whereas the 
ratio of CBA: antigen were 0.67 + 0.66, 0.68 + 0.58 and 0.84 + 0.66.  It was also observed 
that the level of CBA was significantly-interrelated with the age group. The vWF antigen 
in Malays were slightly higher but the average ratio of vWF activity: antigen was slightly 
lower compared to Caucasians, Indian, Chinese and Thais. 
Conclusion and recommendation:  Similarly with the previous studies, subjects in O 
group had lower vWF profiles compared to non-O. We recommended to set up cut-off 
0.6 for the ratio of vWF activity: antigen to improve detection of vWD variance in 
Malays. Molecular study among Malay vWD patients is suggested to find out the 
existence of variant on vWF genes, which may result in a different vWF levels and 
activities in Malays.  It is also suggested that a bigger scale population-based study should 
be administered with the participation of multiple ethnics in Malaysia and for those with 
AB blood type as smaller sample size has been a limitation in this study. 
Keywords: von Willebrand Factor profiles, Malays, ABO blood group 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 OVERVIEW 
1.1.1 von Willebrand Factor (vWF) 
vWF is a plasma protein that mediates the initial adhesion of platelets at the sites of 
vascular injury. It also acts as a carrier for blood clotting Factor VIII (FVIII) and stabilizes 
the factor, hindering it from proteolysis in the circulation (Sadler, 1998). Therefore, any 
defect in vWF can cause bleeding due to impaired platelet adhesion capability or by 
reducing the concentration of FVIII. 
vWF is synthesized by the endothelial cells (EC) throughout the body and stored in 
weibel-palade bodies. The small amount of the factors is synthesized by megakaryocytes 
and stored in the alpha granule of the platelets (Sadler, 1998). vWF is a large multimer 
glycoprotein, ranging in size from 500,000 to more than 20 million daltons with more 
than 2 micrometres in length (Mohanty and Shetty, 2014). It is coded by a gene located 
at a short arm of chromosome 12 (Ginsburg et al., 1985). ADAMTS13 is a plasma 
metalloprotease that cuts the vWF protein at the peptide bond Tyr1605-Met1606 
(Doldan‐Silvero et al., 2008). It will rapidly reduce the size of the vWF multimer at the 
time it is secreted into the plasma thus determining the vWF’s specific activity. The 
interaction of vWF with the platelet and collagen depends on the size of its multimers. 
The most effective size to assist wound healing are 5000–10 000 kilo daltons, under 
conditions of high shear stress (Stockschlaeder et al., 2014). 
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As an acute phase reactant protein, the levels of vWF in circulation varies.  It is increased 
during acute infectious illnesses and dropped after the recovery period (Pottinger et al., 
1989). The level also varies among normal individuals or when measured repeatedly 
among the same individuals (Werner et al., 1995). Orstavik (1985) reported that most 
(60%) of the reasons for the variance among individuals were due to genetic factors in 
which 30% of that, was due to the effect of ABO blood type (Orstavik et al., 1985). 
The fate of the vWF in circulation depends on the size of the protein multimer, the 
interaction with the platelet or other cells, the exposure to ADAMTS13 for proteolysis 
and the rate of clearance in the liver or spleen (Sadler, 2009). 
1.1.2 von Willebrand Disease (vWD) 
vWD is the commonest hereditary bleeding disorder worldwide. The disease is a highly 
heterogeneous disorder with bleeding event, ranging from asymptomatic or very minimal 
bleeding symptom to very severe life threatening haemorrhage (Mohanty and Shetty, 
2014). It is caused by the deceased amount or abnormal function of the vWF protein. 
There are 3 types of vWD that have been reported. vWD Type 1 and 3 are due to 
quantitative defect of vWF protein, whereas Type 2 is caused by qualitative defects of the 
protein. In vWD Type 1, there is a minimal deficiency of plasma vWF whereas in vWD 
Type 3, the level of the factor in circulation is very low or almost nil. 
The mild quantities deficiency of vWF in vWD Type 1 leads to mild bleeding tendency 
while in Type 3 leads to life threatening bleeding events. Table 1.1 showed the 
classification of vWD as adapted from (Gill, 2004). 
 
 
3 
 
Table 1.1 Classification of von Willebrand disease (Gill, 2004).  
 
vWD type Prevalence Pathophysiologic 
characteristics 
Diagnostic vWF Assays 
Type 1 1–2% of 
general 
population; 
70–80% of 
vWD 
Decreased amount of 
normal vWF. 
Proportionally decreased vWF 
RiCof and vWF Ag with normal 
multimers; Factor VIII C variably 
decreased. 
Type 3 1:250,000 Complete absence of 
vWF. 
Absent vWF RiCof, vWF Ag, and 
vWF multimers; Factor VIII C 3–
5%. 
Type 2A 10% of 
diagnosed 
vWD 
Failure of mutant vWF 
to multimerize or 
increased proteolysis 
of mutant vWF. 
Decreased vWF RiCof, normal or 
decreased vWF Ag, absent high 
and intermediate molecular 
weight multimers. 
Type 2B Rare 20% 
of vWD 
Type 2 
Adsorption of high 
molecular weight 
mutant vWF 
multimers from 
plasma due to 
increased binding to 
platelet glycoprotein 
1b (GP 1b). 
Decreased vWF RiCof, normal or 
decreased vWF Ag, absent high 
molecular weight multimers, 
increased RIPA at low-dose 
ristocetin, increased vWF binding 
to normal platelets, 
thrombocytopenia. 
Type 2M Rare Abnormal vWF 
binding site for 
platelet GP 1b. 
Decreased vWF RiCof, normal or 
decreased vWF Ag, normal vWF 
multimer structure, decreased 
vWF binding to normal platelets. 
Type 2N Rare Abnormal vWF 
binding site for Factor 
VIII. 
Normal vWF RiCof, normal 
vWF: Ag, normal vWF multimer 
structure, decreased Factor VIII 
C, decreased Factor VIII binding 
to vWF. 
Platelet-
type 
Rare Adsorption of high 
molecular weight vWF 
multimers from 
plasma due to 
increased binding to 
mutant platelet GP 1b. 
Decreased vWF RiCof, normal or 
decreased vWF antigen, absent 
high molecular weight multimers, 
increased RIPA at low-dose 
ristocetin, normal vWF binding to 
normal platelets, 
thrombocytopenia. 
vWF: von Willebrand Factor, vWF Ag: von Willebrand Factor antigen, vWF RiCof: von Willebrand Factor 
Ristocetin Cofactor Assay, RIPA: Ristocetin-induced platelet aggregation, Factor VIII C : Coagulation 
Factor VIII 
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The heterogeneous of the disease presentations and the laboratory findings which may 
overlap with normal subjects, make it challenging for the clinicians to establish the 
diagnosis of vWD. The molecular study may correspond to the specific variants, but has 
a wide range of genetic mechanisms (Fernández and de Alarcón, 2014). 
Currently, diagnosis of vWD is based on an array of laboratory tests (vWF antigen, Factor 
VIII, vWF Ristocetin Cofactor Assay and VwF Collagen Binding Assay) together with 
the history of increased bleeding tendency, which usually is also present in the family 
members. The blood investigation should be carried out in a dedicated laboratory that is 
qualified to perform all the tests correctly and providing the patients with a balanced view 
of their bleeding risks. In Malaysia, the National Blood Centre in Kuala Lumpur is one 
of the accredited laboratories to perform all of these tests. 
Family and patient’s bleeding history are very important in determining the diagnosis of 
vWD and serve better prediction of future bleeding than depending only on plasma vWF 
level. Further testing on subjects with the vWF level of 30 to 50 IU/dL will not identify 
the clinically significant patients whereas testing on the bleeding patients will identify 
only the relatively small number of patients with clinical severity of vWD Type 1, 2 and 
3, and larger numbers with a moderately low vWF level. (Sadler, 2009). However, the 
high prevalence of mild bleeding symptoms even in a normal individual requires the 
usage of a standardized questionnaire and bleeding score for the identiﬁcation of patients 
who require further laboratory evaluation for vWD (Rodeghiero et al., 2005). In the 
current study, we used the standardized questionnaire extracted from Guidelines from the 
National Heart, Lungs, And Blood Institute (NHLBI) 2008 (Nichols et al., 2008) as a 
screening tool to exclude any bleeding tendencies in donors and their family members. 
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The Table 1.2 is the guideline from the NHLBI, United States of America (USA) to 
diagnose vWD. Currently National Blood Centre, KL followed the NHLBI guideline and 
the treatment given to the patient were depended on the severity of the bleeding and the 
type of the disease. 
Table 1.2 Guideline to diagnose vWD (National Heart, Lung, And Blood Institute-2008). 
Condition Description FVIII 
(IU/dL) 
vWF Ag 
(IU/dL) 
RiCof 
(IU/dL) 
RiCof/ 
vWF Ag 
Type 1 Partial quantitative vWF 
deficiency (75% of 
symptomatic vWD).  
↓ or 
normal. 
<30 <30 >0.5-0.7 
Type 2A Low vWF-dependent 
platelet adhesion with 
selective deficiency of high-
molecular-weight multimer. 
↓ or 
normal. 
<30-200 <30 <0.5-0.7 
Type 2B Increase affinity for platelet 
GP 1b. 
↓ or 
normal. 
<30-200 <30 Usually 
<0.5-0.7 
Type 2M Low vWF-dependent 
platelet adhesion without 
selective deficiency of high-
molecular-weight multimer. 
↓ or 
normal. 
<30-200 <30 <0.5-0.7 
Type 2N Markedly decrease binding 
affinity for FVIII. 
↓↓ 30-200 30-
200 
>0.5-0.7 
Type 3 Virtually complete 
deficiency of vWF (severe, 
rare). 
↓↓↓ 
(<10IU/dl). 
<3 <3 Not 
applicable 
Low vWF  Normal. 30-50 30-
50 
>0.5-0.7 
Normal  Normal. 50-200 50-
200 
>0.5-0.7 
vWF: von Willebrand Factor, vWF Ag: von Willebrand Factor antigen., vWF RiCof: von Willebrand Factor 
Ristocetin Cofactor Assay, FVIII: Factor VIII 
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Currently, the National Blood Centre, KL followed the NHLBI guidelines and the 
treatment given to the patients are dependent on the severity of the bleeding and the types 
of the disease. 
The NHLBI chose the vWF antigen and RiCof of less than 30 IU/dL as the level for a 
definitive diagnosis of vWD because of the high prevalence of the O blood group in the 
United States of America (USA) which is associated with low vWF antigen levels, the 
absence of genetic abnormality in patients with mild to moderate level of RiCof and the 
presence of a significant number of individuals with a bleeding history but no underlying 
disease detected. 
The absent of vWF (vWD Type 3) and many qualitative defects (vWD Type 2) are 
straightforward diagnosis but not in vWD Type 1 due to a broader distribution of normal 
vWF level, the high prevalence of mild bleeding symptoms even in a normal person and 
the weak relationship between vWF level and bleeding event. Therefore, none of the vWF 
level can isolate patients into a group with clearly different clinical features (Sadler, 
2003). Consequently, many vWD Type 1 patients do not have the specific bleeding 
disease at all which limits the value of the diagnosis. False positive diagnosis of vWD 
Type 1 also causes many patients to be subjected to risky, expensive and ineffective 
treatments, while the actual causes of symptoms are overlooked and untreated. Many 
patients had to change their lifestyles due to fear of bleeding and some have even been 
denied of insurance coverage. 
Recent studies of vWD Type 1 patients have defined several pathophysiologic 
mechanisms that determine the vWF plasma concentration but the relationship between 
the vWF levels and the probability of bleeding remains inconclusive and the difference 
between ‘normal’ and ‘low’ is undistinguishable. These problems might be resolved by 
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an epidemiologic approach to vWF and other risk factors for the bleeding event (Sadler, 
2009). 
The treatment of vWD is dependent on the severity of the bleeding symptoms, the type 
of the disease and the type of surgical procedure that the patient plans to proceed with. 
The treatments include drugs to induce the releasing of vWF and FVIII into the blood 
circulation to prevent lysis of the blood clots, to control heavy menstrual bleeding in 
women and to replace the vWF.  
While inherited vWD is the commonest inherited bleeding disorder, acquired vWD is a 
rare bleeding disorder. It is associated with other diseases such as lymphoproliferative or 
myeloproliferative disorders, malignancies, immunologic diseases, various congenital 
cardiac defects or other drug related ailements. The production and function of vWF in 
this type of diseases are normal, but the factor is rapidly eliminated from circulation by 
autoantibodies, absorption of the vWF onto the cancer cell clones or loss of high-
molecular-weight vWF multimers under the high shear stress (Federici, 2006). 
1.1.3 von Willebrand disease: Epidemiology 
Previously, vWD is classified as a rare disease (Office of Rare Diseases of the National 
Institutes of Health, US). However, Rodeghiero (1987) revealed that the prevalence of 
the Italian population with vWD was between 0.57%-1.15%  (Rodeghiero et al., 1987). 
Meanwhile, Werner (1993) showed that the prevalence among the USA population was 
at 1.3% (Werner et al., 1993). In 2010, Bowman reported that there were relatively low 
prevalence of medically signiﬁcant bleeding patients attending primary health clinics and 
a low prevalence of symptomatic vWD in the primary care setting which was at least 1 in 
1000. They suggested that further investigations needed to be carried out to investigate 
the discrepancies of these prevalent findings (Bowman et al., 2010). 
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The disease shows no geographical nor ethnic preferences. As an autosomal disorder, 
both genders inherit the mutant vWF alleles equally, but women show frequent bleeding 
symptoms by almost 2:1 probably because of the excessive per vaginal bleeding during 
their reproductive age (Lillicrap, 2013). 
Data on the vWD epidemiology in developing countries are very limited. Although there 
is no accurate data on the estimation of vWD prevalence in those countries, the available 
data suggests that the diagnosed cases were less than the actual number, accounting for 
only 6% to 13% of patients with hereditary bleeding disorders. The number with severe 
diseases tend to be much higher, particularly in certain parts of the world where 
consanguineous marriage  is common (Srivastava and Rodeghiero, 2005). In Malaysia, 
only 0.002% (n=464) of the diagnosed cases were reported among the 28 million of the 
population (World Federation of Hemophilia, 2010). Most of the patients were diagnosed 
to have vWD Type 1 (77.2%) (Periayah et al., 2016). This corresponds with the estimated 
prevalence in some countries where the symptomatic patients that was seen at 
haemostasis clinics ranging from 23 to 110 per million population (0.0023–0.01%) 
(Nichols et al., 2008). In another study conducted by Hassan (2012), it is found that vWD 
were common among menorrhagia patients who attended the gynaecology clinic in 
Hospital Universiti Sains Malaysia, Kelantan, which accounted up to 13.3%. They 
suggested that vWD testing should be provided to complete the diagnostic work-up for 
menorrhagia (Hassan et al., 2012). It was similar with other studies which reported that 
the frequency of vWD in menorrhagia ranges from 5% to 20% (Kujovich, 2005). 
1.1.4 Malaysia is a multiracial country 
An interesting fact about the Malaysian society is the diversity of its ethnic composition. 
It is the result of large population movements in the nineteenth and early twentieth 
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centuries (Schafgans, 1998). Currently, Malaysia has a population of 31.2 million, 
consisting of 15.3 million of women and 16.4 million of men where 68.6% of them are 
Malays, 23.4% are Chinese, and 7% are Indians and 1% of other ethnic groups 
(https://www.statistics.gov.my/). Therefore, we have decided to perform the study among 
the Malays because it represents  the majority of the country’s population (68.6%) and 
the majority (63.0%) of the vWD patients diagnosed in Malaysia  (Periayah et al., 2016). 
In the National Blood Centre, KL the majority (49.5%) of donors were also Malays 
(Blood Bank Information System [BBIS] National Blood Centre Kuala Lumpur 2015). 
The distribution of the ABO blood group among our blood donors, have been reported by 
Musa in 2012. They revealed about 34.5 % of Malays were in the O group, 27.5% were 
in group B, 30.5% were in group A and 7.5% were in group AB (Musa et al., 2012). In 
addition, Manoharan (2013) also reported that 39% of Malays were in group O, 32% were 
in group B, 23% were in group A and 13% were in group AB as the subjects of the study 
were students at Asia Metropolitan University of Malaysia. In the current study, we 
included the blood group O, A and B of Malay donors, but excluded group AB as it is 
less prevalent among our population (Manoharan et al., 2013; Musa et al., 2012) 
1.1.5 Ethnic variation in von Willebrand Factor 
In previous population studies, they found that vWF were higher among African 
Americans than Caucasians. These racial differences in vWF further complicated the 
issues surrounding a diagnosis of  vWD (Miller et al., 2001). Another study performed in 
South Africa with a distinct ethnic mixture of Africans, Caucasians and Indians reported 
that the African Americans had significantly higher vWF antigen and Factor VIII levels 
when compared to others. However, they found that the Indians had comparable levels of 
vWF with Caucasians. They suggested that the influence of ethnicity on the vWF levels 
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should also be considered in the clinical and laboratory evaluation of vWD (Sukhu et al., 
2003). This is contradictory to the earlier study conducted by Werner (1993), who found 
that there were no significant differences in vWF activity via ethnicity but they only 
carried out the study focusing on the age group of paediatric subjects (Werner et al., 
1993). Later, Johnsen (2013) in the NHLBI exome sequencing project found that some 
vWF missensed variants, which were commonly or uncommonly present among certain 
ethnicity had contributed to the phenotypic variation of the vWF and Factor VIII (Johnsen 
et al., 2013). 
Even when they had different ethnicity than Caucasians, Rojnuckarin (2005) reported that 
the vWF profiles among Thais were comparable with the earlier reports in the USA 
population (Rojnuckarin et al., 2005). 
1.1.6 von Willebrand Factor level influence by ABO group 
ABO blood groups greatly influence the plasma level of vWF as  the O blood group 
subjects have a lower vWF levels compared to non O blood group (Franchini et al., 2007). 
Rojnuckarin (2005) found that AB blood group subjects had the highest level of vWF 
followed by B, A and O (Rojnuckarin et al., 2005). The ABO blood group appeared to 
strongly influence the clearance of vWF, but not its protein synthesis or its release from 
EC (Gallinaro et al., 2008). In a study conducted by Orstavik (1985) revealed that Factor 
VIII was dependent on vWF antigen levels and 30% of the genetic variance of vWF 
antigen were due to the effect of ABO blood group (Orstavik et al., 1985). They also 
found that the concentration of plasma vWF and Factor VIII were the lowest in O, higher 
in A2, and highest in A1 and B group subjects (Orstavik et al., 1985). For the diagnosis 
of vWD among the different ABO blood group, the National Heart, Lung, and Blood 
Institute chose the less than 30 IU/dL plasma vWF level for a definitive diagnosis of vWD 
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because there is a high prevalence of O blood group in the USA which is associated with 
‘low’ vWF levels. They did not use different reference ranges for diagnosing vWD among 
group O individuals. In this current study, we focus on blood group A, B and O as AB 
group is less prevalence among our population, our blood donors and Malay donors at 
NBCKL. 
1.2 List of definitions 
1.2.1 Body mass index: Is a measure of body fat based on height and weight that 
applies to adult men and women. BMI categories:  
Underweight = <18.5 
Normal weight =  18.5–24.9  
Overweight =   25–29.9  
Obesity =   30 or greater 
(http://www.nhlbi.nih.gov/) 
1.2.2 vWF antigen:  Test to measures the quantity of a vWF in the circulation. 
1.2.3 ADAMTS13:  A Disintegrin like And Metalloprotease domain (reprolysin 
type) with ThromboSpondin type 1 motif, member 13]. A 
plasma protein that cleaves multimeric vWF. 
1.2.3 RiCof: Ristocetin Cofactor Activity; test to evaluate the capability 
of vWF to bind platelet glycoprotein 1b (GP 1b) and 
promote platelet plug formation. 
1.2.4 CBA: Collagen Binding Assay; test to evaluate the capability of 
vWF to bind to collagen, mimicking the interaction with 
the subendothelial matrix at the site of vascular injury. 
 (http://practical-haemostssis.com/) 
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1.2.5 Rare disease:  Disease that affects less than 200,000 people in the US 
population.  
(https://www.genome.gov/) 
1.3 Research Justification and Benefits 
vWD is the commonest hereditary bleeding tendency disorder encountered in almost 1% 
of the worldwide population (Kouides and Kreuz, 2009). However, the diagnosis of vWD 
Type 1 is very challenging due to the broad distribution of normal vWF levels, the high 
prevalence of mild bleeding symptoms even in the normal population and the weak 
relationship between vWF levels and the bleeding events.  
In the National Blood Centre, Kuala Lumpur (NBCKL), the interpretation of laboratory 
results for vWF profiles follows the guidelines from the NHLBI. However, the normal 
range that is being used by the NHLBI was established according to the Caucasians 
population. There are several studies found that the levels of vWF and Factor VIII were 
significantly higher in blacks compared to the white population (Fleming, 2003; 
Gomperts et al., 1976; Kadir et al., 1999; Miller et al., 2001) proposed that the reference 
ranges of laboratory haemostasis investigations, cannot be used as a reference across the 
world as the range is largely based on the results obtained from the Caucasians. 
Up to the best of our knowledge, the normal reference range of the vWF profiles in the 
Malaysian population is not established yet. This study will serve as preliminary data of 
the vWF profiles among the Malay population in our country. If the data obtained from 
this study is largely deviated from the NHLBI 2008 data, we then have to conduct a larger 
scale population-based study in the future to obtain our own normal vWF profiles 
reference range. It may include the 3 major races in Malaysia (Malays, Chinese and 
Indians), including all ABO blood groups. 
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There are limited studies on vWF levels among the Asian compared to the western 
population. It is hope that this study will serve as a preliminary data on vWF antigen and 
activity levels in the healthy Malay population in Malaysia. 
1.4 Research Objectives 
1.4.1 General Objectives 
To study von Willebrand Factor profiles of the different ABO blood group among Malay 
donors at NBCKL in 2015. 
1.4.2 Specific Objectives 
1) To determine the von Willebrand Factor profiles (Factor VIII, von Willebrand 
antigen, RiCof and Collagen Binding Assay) of the different ABO blood group among 
Malay donors at NBCKL in 2015. 
2) To compare the von Willebrand Factor profiles (Factor VIII, von Willebrand 
antigen, RiCof and Collagen Binding Assay) with the different ABO blood group among 
Malay donors at NBCKL in 2015. 
3) To assess the influence of demographic data (gender, age group and BMI) and smoking 
habit with the von Willebrand Factor profiles among Malay donors at NBCKL in 2015. 
1.5 Research Hypothesis 
1) There are differences in the von Willebrand Factor profiles in different ABO 
blood groups among Malay donors at NBCKL. 
2) There are association between demographic data (gender, age group and BMI) 
and smoking habit, and the von Willebrand Factor profiles among Malay donors 
at NBCKL. 
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1.6 Conceptual Framework 
There are a few factors that may influence the levels of plasma vWF. Some of them are 
stated in the figure below. In the current study, we examined the effect of ABO blood 
group and donors’ demographic data (gender, age group and BMI) and smoking habit on 
the plasma vWF profiles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Factors may affecting the levels of vWF 
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CHAPTER 2 
LITERATURE REVIEW 
2.1 The Malays 
The Malays is the race of people who live mainly in Peninsular Malaysia and a portion 
of the adjacent island of Southeast Asia, including the coast of Borneo, the east coast of 
Sumatra and small islands that lie between these areas (http://sabrizain.org/malaya/). 
Based on their migrations a few centuries ago, there are various sub-ethnic groups in the 
Malay population present currently, which are believed to have different ancestral origins. 
The major sub-ethnics are Melayu Jawa, Melayu Minang, Melayu Bugis, Melayu 
Kelantan and Melayu Kedah (Hatin et al., 2011). Some of the present day Malays are 
mixed with modern Chinese, Indian, Arab and Thai blood (http://sabrizain.org/malaya/). 
Most of the Malays in Malaysia are practising Islam as their religion, speak Malay 
language and practice Malay customs (adat) and cultures.  
The Malays is one of the unique ethnicity in the world with different genetic variances 
compared to others. In the fields of population genetics and forensics, the human X 
chromosome has been focused on by many researchers in recent years. Samejima (2012) 
has carried out a genetic study on  the X-chromosomal short tandem repeats (X- STRs) 
and found 12 X-STRs in the Malay population that differed from East Asian, European, 
or African populations (Samejima et al., 2012). In the genetic study for drug metabolism, 
Teh (2001) found that the genetic polymorphism of CYP2D6 in Malays was different 
from the Chinese and Far Eastern races. These variances result in ethnic differences in 
the metabolism of CYP2D6 drugs (Teh et al., 2001). The genetics differences are also 
present among sub-ethnic group as previously reported by Hatin (2014) and that there is 
a genetic mixture among sub-ethnic Malays in Peninsular Malaysia (Hatin et al., 2011). 
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These genetic variants may increase risk among the Malays to inherit certain diseases or 
resistance to certain drugs.  
2.2 Malays and thromboembolic and bleeding event 
Up to the best of our knowledge, there are very limited published studies on 
thromboembolic or bleeding event among the Malays. Nawawi (2002) reported that the 
prevalence of the coronary risk factors among rural Malays in Malaysia was high 
according to the Global Risk Assessment. Apart from genetic predisposition, the high 
prevalence was probably due to the rapid socioeconomic development at the rural areas 
(Nawawi et al., 2002). Loo (2012) had described a few studies on the prevalence of stroke 
(bleeding or ischaemic)  in different states in Malaysia where they found about 86·1% of 
the patients were Malays and 13·9% were Chinese in Kelantan whereby 55.7% were 
Chinese, 28.9% were Malays and 14.2% were Indians in Pulau Pinang (Loo and Gan, 
2012). This may reﬂect upon the local population as many Malays reside in Kelantan 
compared to the majority of Chinese located in Pulau Pinang especially on the island. 
However, these also may reflect the differences of genetic among the ethnicity which 
results in different risks of thromboembolic or bleeding incident. In 2004, Kandasami had 
conducted a study to look into the prevalence of bleeding events (peptic ulcer disease) 
among different ethnicity in Malaysia and found over  presented symptoms in the Chinese 
but  similar to the ethnic distribution in the Malays and Indians (Kandasami et al., 2004).  
2.3 Malays and von Willebrand disease 
Apart from collecting, processing and distributing of blood and its components to 
hospitals, the National Blood Centre, Kuala Lumpur also provides expert medical 
services and groundwork for research in the field of haematology. Based on the recent 
update from the National Blood Centre, the effect of vWD was quite low among 
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Malaysians due to under reporting even after many conferences, campaigns, awareness 
and colloquia that have been organized. Only 545 cases were reported from the year 1979 
to 2013 (Periayah et al., 2016). The prevalence was highest in the Malays (63%) followed 
by Indians (15.2%) and lowest in Chinese (5.5%) Most of the patients were diagnosed to 
have vWD Type 1 and about 40% of them were males and 60% were females (Periayah 
et al., 2016). 
2.4 Diagnosis of von Willebrand disease 
vWD is a heterogeneous disorder and a very complex disease (Sadler and Gralnick, 1994). 
It is very difficult to establish the diagnosis of vWD especially in Type 1 disease due to 
the wide distribution of the normal vWF level, high prevalence of mild bleeding 
symptoms even in a normal population and the weak relationship between vWF levels 
and bleeding events. In Type 1, the vWF level is not obviously low, but usually near to 
the lower end of the normal vWF range. The wide distribution of vWF levels in a normal 
population, makes the situation more complicated. Almost 95% of the plasma vWF levels 
lie between 50 to 200 IU/dL among the 300 million of the USA population and around 
7.5 million people who had the vWF levels less than 50 IU/dL would be at risk for the 
diagnosis of vWD Type 1 (Nichols et al., 2008). The cut-off level of 50 IU/dL was chosen 
as normal because less than that showed increased bleeding risk with a relative risk of 
2.0-3.9 (Sadler, 2003). 
Nitu-Whalley (2000) had conducted a retrospective study to investigate the difficulties in 
making a diagnosis of vWD Type 1 in one of the Hemophilia Centre in United Kingdom 
(Nitu-Whalley et al., 2000). They found that among previously diagnosed vWD Type 1, 
41% of them were in group O and had between 30-50 IU/dL of vWF levels, with or 
without a history of increase in bleeding tendencies. Those groups of patients might 
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require reclassification as ‘not vWD’ and searching for alternative diagnosis for the 
bleeding symptoms might be needed.  
In view of the bleeding history, the standardized questionnaire is extremely important to 
screen bleeding risks among the population. Rodeghiero (2005) proposed the use of a 
standardized questionnaire and bleeding score to identify the patients who need 
laboratory evaluation for the vWD (Rodeghiero et al., 2005). Friberg (2006) observed 
that about 23% of Swedish girls reported 3 or more haemorrhagic symptoms when using 
a self-reported questionnaire (Friberg et al., 2006), whereas Rodeghiero (2005) revealed 
that by using a standardized questionnaire, they found less than 1% of normal control had 
3 or more of the symptoms (Rodeghiero et al., 2005). 
Apart from the bleeding history, the diagnosis of vWD is also based on an array of 
laboratory tests to investigate the amount and function of the protein. The tests looked at 
the amount of vWF (vWF antigen) and determining the activity of the protein; to carry 
and stabilize the Factor VIII (Factor VIII Assay), to bind to the glycoprotein 1b on the 
platelet surface (vWF RiCof) and to bind to the collagen (vWF CBA). The primary site 
of platelet binding is in the A1 domain of vWF, whereas collagen binding is in the A3 
domain. The interaction of platelets with vWF is forced in vivo by shear stress, which 
causes a conformational change of the protein and allows its binding to the platelet 
glycoprotein 1b (Sadler, 1998). In vitro, the interaction is aggravated by the antibiotic 
ristocetin, in the lack of shear stress condition (Scott et al., 1991). 
Similar to the vWF RiCof, vWF CBA relies on the size of the vWF multimeric in which 
the larger size will bind more avidly than the smaller forms. However, Dean (2000) 
conducted a study to compare the vWF CBA and vWF RiCof and found that the vWF 
CBA was most helpful in the classification of vWD Type 2 variants, using a low vWF 
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activity: vWF antigen ratio (Dean et al., 2000). Similarly, Casonato (2001) observed that 
in disease Type 2A and 2B, even when both vWF CBA and vWF RiCof were decreased, 
the vWF CBA was more constant and they suggested to include vWF CBA to the test 
panel for diagnosis of vWD (Casonato et al., 2001). A ratio of vWF CBA: vWF antigen 
of  less than 0.5 is consistent with types 2A and 2B disease, whereas a normal ratio (0.5 
or more) are associated with types 2M and 2N disease (Popov et al., 2006). Flood (2013) 
found that vWF CBA provides a sensitive method to capture the variant of vWD 
especially by using the lowest (0.6) cut-off of vWF CBA: vWF antigen ratio (Flood et 
al., 2013).  
In early 2000, Favaloro reported that the ability to discriminate the subtype of vWD was 
dependant on the type of collagen used in CBA in which Type III or a mixture of Type 
I/III showed highest sensitivity (Favaloro et al., 2000). In the current study, we used 
collagen Type III to accurately discriminate the subtype if found. Riddell (2002) reported 
that even if vWF CBA is a sensitive method to detect functional variants related to the 
loss of high molecular weight multimers, it’s incapable to detect defective platelet-
binding vWD variants in the presence of normal high molecular weight multimers but 
vWF RiCof does. They concluded that the vWF CBA should be used in association with 
vWF RiCof rather than as a replacement for it (Riddell et al., 2002). A guideline from the 
UK Hemophilia Centre Doctors’ Organization, 2014 also recommended to use both vWF 
RiCof and CBA to increase the ability to detect Type 2 variants and clear definition of 
vWD Type 1 (Laffan, M.A et al., 2014).  
An alternative to vWF RiCof, some laboratories offer vWF-Activity (vWF-Ac) to assess 
the function of vWF to bind to the platelet receptors without the presence of ristocetin. 
Geisen (2014) in a comparison study between vWF activity and vWF RiCof on 
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aggregometer showed a good correlation between the two methods (Geisen et al., 2014). 
Other laboratory tests such as Ristocetin Induced Platelet Aggregation (RIPA) and 
multimeric analysis are also essential in order to differentiate the different subtypes of 
vWD. 
Apart from that, molecular study is also one of the methods to distinguish vWD and its 
variants. vWD is highly heterogeneous due to the molecular mechanisms that produce 
various clinical presentation and laboratory findings. However, the requirement for the 
study in vWD is variable because the usefulness of genetic testing varies for different 
vWD subtypes. In case of vWD Type 1, the picture of the disease is not really clear as the 
causative molecular defect is unidentified in a significant number of cases, and even in 
those cases in which the causative mutation is known. The association of molecular 
pathology is not necessarily understood (Keeney et al., 2008). Although genetic analysis 
is not mandatory to diagnose vWD or to define a classification type, it may be useful in 
isolated situations (Favaloro et al., 2010). 
Nowadays, various tests are available to diagnose vWD, however NHBLI in their 
guidelines suggested carrying out three initial tests namely vWF antigen, vWF RiCof and 
Factor VIII (Nichols et al., 2008). If one or more results is noted to be abnormal, further 
test such as vWF CBA, RIPA, Factor VIII binding, platelet vWF studies, multimer 
distribution, ratio of vWF RiCof: vWF antigen and molecular study are recommended to 
distinguish the type of vWD and its variants. In NBCKL, vWD patients are normally 
classified based on the 3 essential laboratory investigations namely Factor VIII, vWF 
antigen and vWF CBA (Periayah et al., 2016). However, in the current study, we 
performed a full investigation panel of vWF profiles including vWF RiCof. 
 
